Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments

Drug Metabolism and Disposition

Volumn 28, Issue 4, 2000, Pages 475-481

  Komatsu, Kanji ^a   Ito, Kiyomi ^b   Nakajima, Yukiko ^a   Kanamitsu, Shin Ichi ^a   Imaoka, Susumu ^c   Funae, Yoshihiko ^c   Green, Carol E ^d   Tyson, Charles A ^d   Shimada, Noriaki ^e   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SRI INTERNATIONAL   (United States)

^e DAIICHI PURE CHEMICALS CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SULFADIAZINE; SULFADIMETHOXINE; SULFAFURAZOLE; SULFAMETHOXAZOLE; SULFAMONOMETHOXINE; SULFAPHENAZOLE; SULFAPYRIDINE; SULFONAMIDE; TOLBUTAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; KINETICS; MALE; PRIORITY JOURNAL;

ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYLATION; HYPOGLYCEMIC AGENTS; MALE; MICROSOMES, LIVER; MIDDLE AGED; RECOMBINANT PROTEINS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SULFONAMIDES; TOLBUTAMIDE;

EID: 17044450722     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Back DJ and Orme ML'E (1989) Genetic factors influencing the metabolism of tolbutamide. Pharmacol Ther 44:147-155.
2. Back DJ, Tjia JF, Karbwang J and Colbert J (1988) In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines, Br J Clin Pharmacol 26:23-29.
3. Bischoff KB, Dedrick RL, Zaharko DS and Longstretth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60:1128-1133.
4. Böhni E, Fust B, Rieder J, Schaerer K and Havas L (1969) Comparative toxicological, chemotherapeutic and pharmacokinetic studies with sulphormethoxine and other sulphonamides in animals and man. Chemotherapy 14:195-226.
5. Bourrie M, Meunier V, Berger Y and Fahre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
6. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS and Guengerich FP (1989) Expression of a human liver cytochrome P450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28:4993-4999.
7. Christensen LK, Hansen JM and Kristensen M (1963) Sulphaphenazole induced hypoglycemic attacks in tolbutamide-treated diabetes. Lancet 2:1298-1301.
8. Csillag K, Vereczkey L and Gachalyi B (1989) Simple high-performance liquid chromatographic method for the determination of tolbutamide and its metabolites in human plasma and urine using photodiode-array detection. J Chromatogr 490:355-363.
9. Dedrick RL (1973) Animal scale-up. J Pharmacokinet Biopharm 1:435-461.
10. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkelt DJ, Sansom LN and McManus ME (1991) Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 31:125-130.
11. Hansen JM and Christensen LK (1977) Drug interactions with oral sulphonylurea hypoglycaemic drugs. Drugs 13:24-34.
12. Ho JW and Moody DE (1992) Determination of tolbutamide hydroxylation in rat liver microsomes by high-performance liquid chromatography: Effect of psychoactive drugs on in vitro activity. Life Sci 52:21-28.
13. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y and Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Biochem Pharmacol 51:1041-1050.
14. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y and Sugiyama Y (1998a) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
15. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998b) Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 50:387-411.
16. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CA, Tyson CA and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
17. Iwatsubo T, Hirota N, Ooie T, Suzuki H and Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273-310.
18. Knodell RG, Hall SD, Wilkinson GR and Guengerich FP (1987) Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition J Pharmacol Exp Ther 241:1112-1119.
19. Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J and Hansen JM (1975) Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism. Clin Pharmacol Ther 17:731-735.
20. Miller AK, Adir J and Vestral RE (1990) Excretion of tolbutamide metabolites in young and old subjects. Eur J Clin Pharmacol 38:523-524.
21. Miners JO, Foenander T, Wanwimolruk S, Gallus AS and Birkett DJ (1982) The effect of sulfinpyrazone on oxidative drug metabolism in man: Inhibition of tolbutamide elimination. Eur J Clin Pharmacol 22:321-326.
22. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes: Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 37:1137-1141.
23. Montandon B, Roberts RJ and Fischer LJ (1975) Computer simulation of sulfobromophthalein kinetics in the rat using flow-limited models with extrapolation to man. J Pharmacokinet Biopharm 3:277-290.
24. Pond SM, Birkett DJ and Wade DN (1977) Mechanisms of inhibition of tolbutamide metabolism: Phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin Pharmacol Ther 22:573-579.
25. Relling MV, Aoyama T, Gonzalez FJ and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-447.
26. Scott J and Poffenharger PO (1979) Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 28:41-51.
27. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations inhuman liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-422.
28. Srivastava PK, Yun C, Beaune PH, Ged C and Guengerich FP (1991) Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 40:69-79.
29. St-Hilaire S and Belanger PM (1989) Simultaneous determinations of tolbulamide and its hydroxy and carboxy metabolites in serum and urine: Application to pharmacokinetic studies of tolbutamide in the rat. J Pharm Sci 78:863-866.
30. Sugita O, Sawada Y, Sugiyama Y, Iga T and Hanano M (1984a) Effect of sultaphenazole on tolbutamide distribution in rabbits: Analysis of interspecies differences in tissue distribution of tolbutamide. J Pharm Sci 73:631-634.
31. Sugita O, Sawada Y, Sugiyaim Y, Iga T and Hanano M (1984b) Kinetic analysis of tolbutamide-sulfonamide interaction in rabbits based on clearance concept. Prediction of species difference from in vitro plasma protein binding and metabolism. Drug Metab Dispos 12:131-138.
32. Sugiyama Y, Iwatsubo T, Ueda K and Ito K (1996) Strategic proposal for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: Pharmacokinetic consideration. J Toxicol Sci 21:309-316.
33. Thiessen JJ and Rowland M (1977) Kinetics of drug-drug-interactions in sheep: Tolbutamide and sulfadimethoxine. J Pharm Sci 66:1063-1070.
34. Thomas RC and Ikeda GJ (1966) The metabolic fate of tolbutamide in man and in the rat. J Med Chem 9:507-510.
35. Ueda M, Orita K and Koizumi T (1972) Studies on metabolism of drugs. 13. Quantitative separation of metabolites in human urine after oral administration of sulfisomezole and sulfaphenazole. Chem Pharm Bull 20:2047-2050.
36. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP, Gasser R, Meyer UA and Birkett DJ (1993) Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 289:533-538.
37. Veronese ME, McManus ME, Laupattarakasem P, Miners JO and Birkett DJ (1990a) Tolbutamide hydroxylation by human, rabbit and rat liver microtomes and by purified forms of cytochrome P-450. Drug Metab Dispos 18:356-361.
38. Veronese ME, Miners JO, Randles D, Gregov D and Birkett DJ (1990b) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403-411.
39. Vree TB, Beneken Kolmer EW and Hekster YA (1990a) High pressure liquid Chromatographic analysis and preliminary pharmacokinetics of sulfaphenazole and its N2-glucuronide and N4-acetyl metabolites in plasma and urine of man. Pharm Weekbl (Sci) 12:243-246.
40. Vree TB, Beneken Kolmer EW, Hekster YA, Shimoda M, Ono M and Miura T (1990b) Pharmacokinetics. N1-glucuronidation, and N4-acetylation of sulfa-6-monomethoxine in humans. Drug Metab Dispos 18:852-858.
41. Vree TB, Beneken Kolmer EW, Martea M, Bosch R, Hekster YA and Shimoda M (1990c) Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfadimethoxine in man Pharm Weekbl Sci 12:51-59.
42. Weinstein L, Madoff MA and Samet CA (1960) The sulfonamides. N Engl J Med 263:793-800, 842-849, 900-907.
43. Wing LMH and Miners JO (1985) Cotrimoxazole as an inhibitor of oxidative drug metabolism: Effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. Br J Clin Pharmacol 20:482-485.
44. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.